MarginsXMarginsX
Home › Markets › Health Care › AMRN

Amarin Corporation plc (AMRN)

AMRN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$11.31
-0.62% on the day
Market cap
$233.4M
Micro cap
Revenue · 2025
$213.6M
-6.5% on 2024
Net income · 2025
-$38.8M
-18.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/0001193125-26-085818-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerAMRN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIreland
IPO yearNot reported by the screener
SEC CIK0000897448
SEC industry codePharmaceutical Preparations
Incorporated inUnited Kingdom

Financials · 2025

LineValue
Revenue$213.6M
Net income-$38.8M
Operating income-$50.2M
Net margin-18.2%
Operating margin-23.5%
Revenue growth-6.5%
Cash$134.7M
Total assets$670.8M
P/E (computed)Net income was not positive
P/S (computed)1.1×

Warning signs

Cash runway
Cash-flow positive
$156.5M cash at September 30, 2026
Share count, 1 year
+1.3%
2025-10-31 to 2026-10-31
Going-concern doubt
No
10-Q filed October 28, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-28
Cash and burn$156.5M cash; operating cash flow $9.4M a quarter.Report 2026-09-30
Shares outstanding21,073,239 (2026-10-31); 20,792,684 a year earlier.Cover page 2026-10-31
Reverse splits, 3 years1; latest 1-for-20 on 2025-04-11Source 2025-04-11
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-03-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$39.5M$245K$9.2M$156.5MNo debt tags$176.1M10-Q 2026-10-28
Q2 2026
2026-06-30
$42.2M-$7.7M$6.6M$143.6MNo debt tags$186.2M10-Q 2026-07-29
Q1 2026
2026-03-31
$45.1M-$10.5M$6.4M$131.1MNo debt tags$216.8M10-Q 2026-04-29
Q4 2025
2025-12-31
$49.2M-$1.2M$15.3M$134.7MNo debt tags$213.6M10-K 2026-03-02
Q3 2025
2025-09-30
$49.7M-$7.7M-$12.7M$122.8MNo debt tags$226.7M10-Q 2026-10-28
Q2 2025
2025-06-30
$72.7M-$14.1M$16.6M$147.9MNo debt tags$219.4M10-Q 2026-07-29
Q1 2025
2025-03-31
$42.0M-$15.7M-$12.5M$119.5MNo debt tags$214.1M10-Q 2026-04-29
Q4 2024
2024-12-31
$62.3M-$48.6M-$13.3M$121.0MNo debt tags$228.6M10-K 2026-03-02

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32023-08-02
Latest annual report10-K2026-03-02
Latest quarterly / interim10-Q2026-10-28
Latest current report8-K2026-10-28
Latest proxyDEF 14A2026-04-10

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.0%
1 month-1.7%
3 months-19.6%
Year to date-18.5%
1 year-30.1%
From 52-week high-33.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
VNDAVanda Pharmaceuticals Inc.$3.81-4.51%$230.4M
IMRXImmuneering Corporation$3.52-5.12%$228.0M
ARCTArcturus Therapeutics Holdings Inc.$8.31-0.60%$239.5M
FTHFaeth Therapeutics Inc.$9.28-7.48%$239.8M
BIOABioAge Labs Inc.$5.22-5.95%$239.9M
RCKTRocket Pharmaceuticals Inc.$2.16-6.09%$241.2M
CAMPCAMP4 Therapeutics Corporation$3.86+1.58%$242.2M
LFCRLifecore Biomedical Inc.$6.42-0.08%$243.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier